Total Payments
$239,946
2024 Payments
$31,779
Companies
27
Transactions
271
Medicare Patients
3,365
Medicare Billing
$408,545
Payment Breakdown by Category
Other$122,850 (51.2%)
Consulting$87,481 (36.5%)
Travel$11,677 (4.9%)
Food & Beverage$9,250 (3.9%)
Research$8,589 (3.6%)
Education$98.41 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $122,325 | 44 | 51.0% |
| Consulting Fee | $87,481 | 38 | 36.5% |
| Travel and Lodging | $11,677 | 49 | 4.9% |
| Food and Beverage | $9,250 | 134 | 3.9% |
| Unspecified | $8,589 | 2 | 3.6% |
| Honoraria | $525.00 | 1 | 0.2% |
| Education | $98.41 | 3 | 0.0% |
Payments by Type
General
$231,356
269 transactions
Research
$8,589
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $60,337 | 51 | $0 (2020) |
| Janssen Biotech, Inc. | $59,849 | 49 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $41,738 | 67 | $0 (2023) |
| Genmab U.S., Inc. | $18,788 | 13 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $11,765 | 11 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $10,149 | 10 | $0 (2024) |
| ABBVIE INC. | $8,470 | 14 | $0 (2024) |
| BeiGene USA, Inc. | $5,785 | 9 | $0 (2024) |
| Kite Pharma, Inc. | $3,992 | 3 | $0 (2024) |
| Genentech USA, Inc. | $3,278 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $31,779 | 41 | Genmab U.S., Inc. ($18,775) |
| 2023 | $22,910 | 30 | AstraZeneca Pharmaceuticals LP ($5,750) |
| 2022 | $9,907 | 14 | NOVARTIS PHARMACEUTICALS CORPORATION ($5,820) |
| 2021 | $19,715 | 16 | Janssen Biotech, Inc. ($8,085) |
| 2020 | $13,187 | 11 | Janssen Biotech, Inc. ($8,590) |
| 2019 | $39,923 | 50 | Janssen Biotech, Inc. ($24,811) |
| 2018 | $60,662 | 66 | Janssen Scientific Affairs, LLC ($30,703) |
| 2017 | $41,862 | 43 | Janssen Scientific Affairs, LLC ($29,622) |
All Payment Transactions
271 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | EPKINLY (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $31.55 | General |
| Category: CELLT | ||||||
| 12/19/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $25.68 | General |
| 12/10/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Oncology | ||||||
| 12/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $129.62 | General |
| Category: Oncology | ||||||
| 12/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $161.53 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Novartis Pharmaceuticals Corporation | KYMRIAH (Drug) | Food and Beverage | In-kind items and services | $47.12 | General |
| Category: Oncology | ||||||
| 12/06/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $127.26 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $33.67 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $52.33 | General |
| 11/27/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | Cash or cash equivalent | $14,812.50 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | Cash or cash equivalent | $56.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $77.20 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $66.37 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $31.77 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $19.19 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | In-kind items and services | $373.95 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Travel and Lodging | In-kind items and services | $212.06 | General |
| Category: Oncology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,769.42 | Research |
| Study: Ph1b 2 TDB CHP Pola in NHL for dose escalation Ph1b followed by 1L DLBCL for expansion Ph2 | ||||||
| 09/27/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| 09/11/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $18.86 | General |
| 09/11/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $16.58 | General |
| 08/28/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $12.28 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $5,820 | 1 |
| Ph1b 2 TDB CHP Pola in NHL for dose escalation Ph1b followed by 1L DLBCL for expansion Ph2 | F. Hoffmann-La Roche AG | $2,769 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 817 | 1,258 | $257,069 | $100,390 |
| 2022 | 9 | 912 | 1,326 | $260,810 | $106,448 |
| 2021 | 7 | 832 | 1,344 | $243,883 | $105,615 |
| 2020 | 8 | 804 | 1,335 | $241,122 | $96,092 |
Total Patients
3,365
Total Services
5,263
Medicare Billing
$408,545
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 322 | 539 | $97,871 | $36,140 | 36.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 162 | 297 | $60,244 | $30,761 | 51.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 76 | 76 | $24,760 | $10,144 | 41.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 65 | $16,989 | $5,752 | 33.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 43 | 44 | $19,784 | $5,742 | 29.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 96 | $17,238 | $5,738 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 118 | 124 | $17,108 | $5,076 | 29.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 17 | 17 | $3,075 | $1,037 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 302 | 512 | $79,932 | $34,483 | 43.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 161 | 268 | $46,108 | $28,031 | 60.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 89 | 98 | $46,550 | $14,603 | 31.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 69 | 69 | $21,126 | $8,598 | 40.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 55 | 100 | $24,500 | $7,808 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 157 | 170 | $22,654 | $6,589 | 29.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 47 | 76 | $12,920 | $4,125 | 31.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 16 | 17 | $4,284 | $1,333 | 31.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 16 | 16 | $2,736 | $879.02 | 32.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 296 | 620 | $95,875 | $42,914 | 44.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 145 | 232 | $38,484 | $25,061 | 65.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 65 | 65 | $31,515 | $9,773 | 31.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 193 | 224 | $29,792 | $9,620 | 32.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 66 | 66 | $19,698 | $9,097 | 46.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 65 | $16,069 | $5,168 | 32.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 37 | 72 | $12,450 | $3,982 | 32.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 379 | 731 | $110,626 | $40,007 | 36.2% |
About Dr. Marc Hoffmann, MD
Dr. Marc Hoffmann, MD is a Hematology & Oncology healthcare provider based in Overland Park, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2008. The National Provider Identifier (NPI) number assigned to this provider is 1386806941.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marc Hoffmann, MD has received a total of $239,946 in payments from pharmaceutical and medical device companies, with $31,779 received in 2024. These payments were reported across 271 transactions from 27 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($122,325).
As a Medicare-enrolled provider, Hoffmann has provided services to 3,365 Medicare beneficiaries, totaling 5,263 services with total Medicare billing of $408,545. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Overland Park, KS
- Active Since 06/25/2008
- Last Updated 05/09/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1386806941
Products in Payments
- DARZALEX (Biological) $72,532
- IMBRUVICA (Drug) $50,625
- Imbruvica (Drug) $40,554
- Epkinly (Drug) $18,788
- KYMRIAH (Biological) $11,985
- CALQUENCE (Drug) $8,062
- BRUKINSA (Drug) $5,785
- EPKINLY (Drug) $5,319
- Yescarta (Drug) $3,992
- LUMOXITI (Biological) $1,665
- VENCLEXTA (Drug) $1,301
- VORAXAZE (Drug) $1,068
- KYMRIAH (Drug) $225.08
- clonoSEQ (Device) $146.48
- UKONIQ (Drug) $120.30
- KISQALI (Drug) $116.90
- INTRAROSA (Drug) $110.27
- FARYDAK (Drug) $102.39
- Columvi (Biological) $52.88
- JAYPIRCA (Drug) $51.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Overland Park
Sukumar Ethirajan, M.d, M.D
Hematology & Oncology — Payments: $73,982
Hematology & Oncology $73,982
Robert Talley, Md, MD
Hematology & Oncology — Payments: $3,009
Hematology & Oncology $3,009
Rachana Yendala, Md, MD
Hematology & Oncology — Payments: $2,914
Hematology & Oncology $2,914
Dr. Dhruv Bansal, Md, MD
Hematology & Oncology — Payments: $2,630
Hematology & Oncology $2,630
Richard Mckittrick, M.d, M.D
Hematology & Oncology — Payments: $1,031
Hematology & Oncology $1,031
Dr. Benjamin Powers, Md, MD
Hematology & Oncology — Payments: $782.12
Hematology & Oncology $782.12